ClinicalTrials.gg
RecruitingNCT06144151Updated Jul 16, 2026

A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity

An observational study in Neurotoxicity, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Neurotoxicity Syndromes with a site in United States — 6 open to participants now, 11 under way, 3 of them phase 3. Neurotoxicity Syndromes · United States.

Planned enrollment
8th of 23
100 · median 76
Started
2024
the only one that year
Observational
23 of 76
3 open now
Primary completion
2027-04
later than 6 of 10 live
Registered
71st of 76
by date
Lead sponsor
4 of 76
M.D. Anderson Cancer Center

Among the 76 studies in Neurotoxicity Syndromes with a site in United States, this one is the 8th largest by planned enrollment of the 23 observational ones that give a count, is the only one that started in 2024, is one of 23 observational ones, reaches primary completion later than 6 of the 10 other live ones, and was the 71st registered.

Neurotoxicity Syndromes

133 studies on the registry are indexed under Neurotoxicity Syndromes; 17 are open to participants now.

Browse Neurotoxicity Syndromes studies →

Open to participants now

6 of the 76 studies in Neurotoxicity Syndromes with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Neurotoxicity Syndromes studies recruiting now, 11 (73%) set no upper age limit and 1 (7%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Neurotoxicity Syndromes with a site in United States, or all of them as a file.
02

Study summary

To learn about the relationship between changes in pupil size and reactivity and the start of neurological side effects in patients after receiving CAR-T cell therapy.

Read the detailed description

Primary Objective:

To assess the association between the status of NPi drop from baseline (prior to CAR T-cell infusion) to the lowest NPi post Axi-cel (CD19 CAR-T cell) infusion and the status of immune effector cell-associated neurotoxicity onset within 10 days post CD19 CAR-T cell infusion.

Secondary Objective:

To evaluate the largest absolute difference in NPi between two eyes (∆ NPi) and assess its association with severity of clinical symptoms as measured by Immune Effector Cell Encephalopathy (ICE) and or radiographic / EEG findings

Exploratory Objective:

To assess the feasibility and safety of a pupillometer use in patient treated with Axi-cel therapy.

03

Conditions studied

  • Neurotoxicity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

MD Anderson Cancer Center

Eligibility criteria

Inclusion Criteria:

To be considered eligible for study participation, patient will satisfy all relevant inclusion criteria and none of the exclusion criteria.

Inclusion Criteria:

  1. Ages Eligible for Study: 18 Years and above (Adult, Older Adult)
  2. Sexes Eligible for Study: All
  3. Patient with proven DLBCL, PMBCL or tFL, or follicular Lymphoma receiving axi-cel CAR-T cell therapy in the inpatient setting at MD Anderson Cancer Center
  4. Ability to understand and the willingness to sign a written document.

Exclusion Criteria:

  1. Patients who have already been administered CAR-T cell therapy.
  2. The patient who is unwilling or unable to comply with the requirements of the study including being able to be assessed with pupillometer
  3. Patient has a condition which places him at an unacceptable risk as determined by the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • DeviceNeurOptics® NPi®-300 Pupillometer

    The pupilometer is a non-invasive device which will be placed in front of your eyes, one at a time. It looks like a handheld spotlight or scanner, with a small plastic guide sticking out that will be placed against your cheek to help keep the device in place during the scan. It will not touch your eye. Both your left and right eyes will be measured with the device each time. Scanning with the pupilometer will take less than 5 minutes total for both eyes.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Time frame: Through study completion; an average of 1 year.

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Apr 2027, 37 months after the start.

Of 20 observational studies under Neurotoxicity Syndromes, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18. This study's planned 37 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2023
First posted
Nov 22, 2023
StartActual
Feb 8, 2024
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06144151
Responsible party
Sponsor
First posted
Nov 22, 2023
Start date
Feb 8, 2024
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Jul 16, 2026

Study contacts

Ranjit Nair, MD
Contact
rnair@mdanderson.org
(713) 563-4354
Ranjit Nair, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion